Triptorelin Market, By Product Type (Triptorelin pamoate, Triptorelin acetate, and Triptorelin embonate), By Application (Prostate Cancer, Radical Prostatectomy, Endometriosis, Salivary Gland Cancer and Central Precocious Puberty), By End User (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2029

Triptorelin is a synthetic decapeptide agonist analog of the luteinizing hormone releasing hormone (LHRH). Available is various form such as, solution, injection, powder indicated for the palliative treatment of advanced prostate cancer. Furthermore, the triptorelin is also used for other indications such as treatment of uterine fibroids, endometriosis, and prior to the surgery or when surgery is not deemed appropriate, as well as early onset puberty and female infertility. 

The increasing prevalence of prostate cancer and salivary gland cancer among the young patient is expected to foster the triptorelin market. Further, the adoption of triptorelin is increasing due its higher efficacy and tolerability in suppression of gonadotropin secretion in prostate cancer.  For instance, according to National Organization for Rare Disorders (NORD), 2016 data findings, Central Precocious Puberty (CPP), accounted for 1 to 5 in 10,000 children with a female to male ratio of about 20:1, in U.S.

Further, in 2017 triptorelin got approved as an adjuvant treatment in combination with tamoxifen or aromatase inhibitor for endocrine-responsive early stage breast cancer in the women at high-risk of recurrence for those are confirmed as pre-menopausal after completion of chemotherapy. 

Additionally, increasing research and development activities on triptorelin application is also expected to foster the triptorelin market. For instance, in 2016, collaboration of European Organization for Research and Treatment of Cancer with Debiopharm International SA to investigate Triptorelin for treatment of salivary gland cancer.  

The Triptorelin has been segmented on the basis of drugtype, application, distribution channel, and region.

The drug type segment includes Triptorelin Pamoate, Triptorelin Acetate, and Triptorelin Embonate. 

On the basis of application the Triptorelin is segmented into Prostate Cancer, Radical Prostatectomy, Endometriosis, Salivary Gland Cancer, and Central Precocious Puberty.  

On the basis of distribution channel, the Triptorelin has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. 

On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account major market share as compared to that of other regions.

Key players operating in the market of triptorelin include Ipsen, Bachem, Ferring Pharmaceuticals Pvt Ltd., Chengdu Tiantaishan pharmaceutical Co., Ltd., Tecnofarma, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.), Debiopharm Group, and Arbor

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
   • PORTER’s
   • Investment Outlook
3. Market Preview
   • Executive Summary
   • Key Findings—Global Outlook for Triptorelin Strategies
     • Key Questions this Study will Answer

     • By Product Type (Triptorelin pamoate, Triptorelin acetate, and Triptorelin embonate)

       By Application (Prostate Cancer, Radical Prostatectomy, Endometriosis, Salivary Gland Cancer and Central Precocious Puberty)

       By End User (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)

       By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Overview
   • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
   • Y-o-Y Growth Analysis (%), 2020 – 2030
   • Regional Trends
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Regional Analysis
   • Regional Revenue Analysis
   • Regional By segment Analysis
   • Reasons for regional growth
   • Key Player of particular region
   • Countries Include in the report:

1. • • North America (U.S., Canada)
     • Europe (UK, France, Germany, Russia, Italy, Rest of Europe)
     • Asia Pacific (India, Japan, South Korea, China, Rest of Asia Pacific)
     • Latin America (Brazil, Mexico, Rest of Latin America)
     • Middle East & Africa (GCC, Israel, South Africa, Rest of Middle East)

1. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
   • Competitive Overview
   • Competitive Benchmarking
   • Market Share Analysis
   • Key Developments In The Triptorelin Market
   • Key Developments: Mergers & Acquisitions
   • Key Developments: Collaboration
   • Key Developments: Contracts & Agreements
   • Key Developments: Expansion
   • Key Developments: Product Developments
2. Company Profiles

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies
• SWOT Analysis

• • Ipsen, Bachem

  • Ferring Pharmaceuticals Pvt Ltd.

  • Chengdu Tiantaishan pharmaceutical Co., Ltd.

  • Tecnofarma

  • Dr. Reddy’s Laboratories Ltd.

  • Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.)

  • Debiopharm Group

  • Arbor Pharmaceuticals, LLC.

1. The Last Word
   • Future Impact
   • About Us
   • Contact